The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines
- Author:
Young Sup WOO
1
;
Won-Myong BAHK
;
Jeong Seok SEO
;
Young-Min PARK
;
Won KIM
;
Jong-Hyun JEONG
;
Se-Hoon SHIM
;
Jung Goo LEE
;
Seung-Ho JANG
;
Chan-Mo YANG
;
Sheng-Min WANG
;
Myung Hun JUNG
;
Hyung Mo SUNG
;
Il Han CHOO
;
Bo-Hyun YOON
;
Sang-Yeol LEE
;
Duk-In JON
;
Kyung Joon MIN
Author Information
- Publication Type:Review
- From:Clinical Psychopharmacology and Neuroscience 2022;20(1):37-50
- CountryRepublic of Korea
- Language:English
- Abstract: The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) first was published in 2002, and has been revised four times, in 2006, 2012, 2017, and 2021. In this review, we compared recommendations from the recently revised KMAP-DD 2021 to four global clinical practice guidelines (CPGs) for depression published after 2010. The recommendations from the KMAP-DD 2021 were similar to those from other CPGs, although there were some differences. The KMAP-DD 2021 reflected social culture and the healthcare system in Korea and recent evidence about pharmacotherapy for depression, as did other recently published evidence-based guidelines. Despite some intrinsic limitations as an expert consensus-based guideline, the KMAP-DD 2021 can be helpful for Korean psychiatrists making decisions in clinical settings by complementing previously published evidence-based guidelines, especially for some clinical situations lacking evidence from rigorously designed clinical trials.
